Author

Naveenchandra Suryadevara

h-index 18 View on Semantic Scholar

We have 3 of 50 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Potently neutralizing and protective human monoclonal antibodies against the measles fusion protein trimer.

Measles remains a significant source of morbidity and mortality globally. There are currently no licensed treatments for patients at high risk of severe disease. There is limited knowledge about the human antibody response to a measles infection or vaccination or the structural determinants of antibody-mediated neutral...

Laura S. Handal, E. Binshtein, Nurgun Kose et al. · Cell Reports Medicine · 0 citations

Sep 2026

A Label-Free, Real-Time Impedance-Based Method for High-Throughput Antiviral Screening.

Impedance-based technologies provide a robust and objective means to quantify cytopathic effects (CPE) in cell culture monolayers, overcoming the limitations of traditional endpoint or visually subjective assays. Cytolytic viruses typically induce pronounced morphological changes and cell death in infected cultures, ma...

Ashley Zolfaghari, Naveenchandra Suryadevara, Jing Zhang et al. · Journal of Visualized Experi... · 0 citations

Aug 2026

Convergent IGHV3-53/3-66 antibodies elicited by Omicron BA.1 infection broadly neutralize emerging SARS-CoV-2 variants

G germline revertant analysis of the COV2-3731 mAb provided additional insights into how this COV2-3731 and other IGHV3-53/3-66-encoded public antibodies evolve to gain breadth against antigenically distinct SARS-CoV-2 variants such as BA.2.3.2, BA.3.1, KP.2.2, and, to some extent, KP.3.3.2.

Naveenchandra Suryadevara, Seth J. Zost, John M. Powers et al. · bioRxiv · 0 citations